EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Lebrikizumab Dosed Every 8 Weeks as Maintenance Provides Durable Response in Adolescent Patients With Moderate-toSevere Atopic Dermatitis

Vikash Oza, Alan Irvine, Vivian Laquer, Peter Lio, Elizabeth Swanson, Kim Papp, Louise DeLuca-Carter, Heidi Crane, Hany Elmaraghy, Yuxin Ding, Meihua Qiao, Amy Susan Paller

SKIN The Journal of Cutaneous Medicine · 2026-11-10 · 10 (6) · s834

DOI: 10.25251/31rhrb86 ↗
AbstractBibliografische Angaben

Abstract

Introduction: In the maintenance periods of ADvocate1 and ADvocate2, efficacy was consistent between the every 2 weeks and every 4 weeks (Q4W) maintenance dosing regimens, and a high proportion of Week 16 responders in the lebrikizumab withdrawal arm exhibited durable efficacy, suggesting less frequent dosing could maintain effectiveness in atopic dermatitis (AD). An extension to the ADjoin long-term study (ADjoin extension) subsequently evaluated the Q8W interval as a maintenance regimen. In the overall ADjoin extension population, Q8W has been reported to provide clinical responses consistent with Q4W dosing. As approximately 10% of adolescents have AD, this analysis describes whether adolescents in the ADjoin extension had a durable response over 32 weeks of Q4W or Q8W dosing. Methods: ADjoin extension was a 32-week study that enrolled patients with AD who had completed the 100-week long-term ADjoin study (NCT04392154) after participation in the parent studies. Key eligibility criteria included being adults or adolescents (≥12–

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →